Palisade Bio (NASDAQ:PALI) (NASDAQ: PALI) is a clinical-stage biotechnology company focused on the discovery and development of novel peptide-based therapeutics. Leveraging its proprietary platform for designing long-acting peptide analogs and protein scaffolds, Palisade Bio aims to address high unmet medical needs in cardiovascular, immunology and oncology indications. The company’s research strategy centers on targeting G protein–coupled receptors (GPCRs) and other key signaling pathways to modulate disease processes with an emphasis on safety and efficacy profiles suitable for chronic treatment.
The company’s lead candidate, PB1046, is a long-acting vasoactive intestinal peptide (VIP) receptor agonist in development for pulmonary arterial hypertension (PAH). PB1046 is designed to dilate pulmonary arteries, inhibit smooth muscle proliferation and reduce vascular inflammation, potentially improving exercise capacity and delaying disease progression in PAH patients. Concurrently, Palisade Bio is advancing PB2452, a monoclonal antibody fragment engineered to rapidly reverse the antiplatelet effects of ticagrelor, which could offer a valuable safety tool for patients on antiplatelet therapy who experience life-threatening bleeding or require urgent surgery.
Beyond these programs, Palisade Bio’s pipeline includes PB5058, a toll-like receptor 8 (TLR8) agonist under investigation for potential immune activation in oncology and heart failure settings. The company conducts preclinical and clinical research in collaboration with leading academic institutions and contract research organizations across North America and Europe. Palisade Bio’s integrated approach to peptide engineering, coupled with its scalable manufacturing partnerships, supports both rapid clinical advancement and long-term commercial readiness.
Founded in 2018 and headquartered in New York with research operations in California, Palisade Bio is led by a management team combining deep experience in peptide therapeutics, clinical development and commercial strategy. President and CEO Andrew Hirsch, Ph.D., has previously held senior roles at Neurocrine Biosciences and Ardea Biosciences, while Chief Scientific Officer George Chronos, Ph.D., brings expertise in GPCR biology and drug discovery. Supported by a board of directors with extensive pharmaceutical and biotech backgrounds, Palisade Bio is positioned to translate its peptide innovation platform into transformative therapies for patients worldwide.
